Scienture Launches REZENOPY Opioid Overdose Emergency Treatment

March 6, 2025

DENVER, Colo., Mar 06, 2025 (247marketnews.com)- Scienture (NASDAQ:SCNX) is attempting to thrust itself into the frontline of the opioid epidemic, as its subsidiary, Scienture, partnered with Kindeva Drug Delivery to launch REZENOPY (naloxone HCl) Nasal Spray 10mg in the U.S. Approved by the FDA on April 19, 2024, this opioid antagonist—touted as the most potent naloxone formulation available— could become a lifeline in an escalating public health crisis.

Kindeva, via its subsidiary Summit Biosciences, will manufacture and supply REZENOPY, leveraging its expertise in nasal drug delivery. Scienture, meanwhile, takes the reins on the New Drug Application (NDA), sales, marketing, and distribution, deploying its robust commercial infrastructure to get this treatment to market.

Narasimhan Mani, Ph.D., MBA, Scienture’s President said, “We are proud to take this significant step in strengthening our commitment to combating the opioid epidemic. Through this collaboration with a well established and strong partner like Kindeva, we now offer REZENOPY, a higher dose naloxone HCl option for communities, reinforcing our mission to deliver impactful healthcare solutions.”

At 10mg, REZENOPY is the highest-strength nasal spray on the market, engineered to counter the deadliest synthetic opioids like fentanyl, which have turbocharged overdose rates. Building on naloxone’s proven track record, REZENOPY amps up its efficacy while retaining the ease of nasal delivery.

Milton Boyer, Kindeva’s CEO, added, “As part of our commitment to fast-tracking healthier tomorrows, we are thrilled to be joining forces with Scienture to bring this life-saving device to market. Our nasal drug delivery team has created a nasal spray that is quick and simple to administer, and which has the potential to prevent unnecessary overdoses across the United States. We are dedicated to ensuring this device reaches the people that need it most as quickly as possible and prevent more opioid related fatalities.”

The opioid crisis isn’t slowing down—it’s evolving. Fentanyl and its ilk made overdoses more lethal, overwhelming weaker interventions. IQVIA data (MAT December 2024) pegs U.S. naloxone sales at $189 million annually, with 10 million units moved.

About 24/7 Market News
As a pioneer in digital financial market media, 24/7 Market News (24/7MN) is dedicated to the swift distribution of financial market news and information. 24/7 MN incorporates comprehensive corporate communications resources and tools to engage the investment community. Visit 24/7 Market News website here.

24/7 MARKET NEWS, INC Disclaimer
Please go to https://247marketnews.com/disclaimer/ for disclaimer information.

CONTACT:
24/7 Market News
Editor@247marketnews.com

Related news for (SCNX)

NASDAQ and NYSE quotes and data are delayed 15 minutes unless indicated otherwise. Market data and exchange information are provided for informational purposes only and is not intended for trading purposes. Neither 24/7 Market News Editors, 247 Market News, or data and content providers shall be liable for any errors or omissions, delays, misquotes or other market information relayed in any press materials. You should Use Realtime data to conduct due diligence before investing or trading, and trading in any stock is risky you could lose all your money.